269 related articles for article (PubMed ID: 33944878)
21. Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine.
Asleh K; Lluch A; Goytain A; Barrios C; Wang XQ; Torrecillas L; Gao D; Ruiz-Borrego M; Leung S; Bines J; Guerrero-Zotano Á; García-Sáenz JÁ; Cejalvo JM; Herranz J; Torres R; Haba-Rodriguez J; Ayala F; Gómez H; Rojo F; Nielsen TO; Martin M
Clin Cancer Res; 2023 Jan; 29(2):389-400. PubMed ID: 36346687
[TBL] [Abstract][Full Text] [Related]
22. Radiation Recall Dermatitis After Capecitabine in a Patient With Triple Negative Breast Cancer.
Laird J; Leventhal J; Kanowitz J; Damast S
Pract Radiat Oncol; 2021; 11(6):448-452. PubMed ID: 34157449
[TBL] [Abstract][Full Text] [Related]
23. Adjuvant capecitabine for HER2-negative breast cancer.
Burki TK
Lancet Oncol; 2017 Jul; 18(7):e375. PubMed ID: 28602775
[No Abstract] [Full Text] [Related]
24. Capecitabine in Combination with Standard (Neo)Adjuvant Regimens in Early Breast Cancer: Survival Outcome from a Meta-Analysis of Randomized Controlled Trials.
Zhang ZC; Xu QN; Lin SL; Li XY
PLoS One; 2016; 11(10):e0164663. PubMed ID: 27741288
[TBL] [Abstract][Full Text] [Related]
25. [Ⅰ.Capecitabine for Adjuvant Therapy in Breast Cancer].
Masuda N
Gan To Kagaku Ryoho; 2020 Dec; 47(12):1673-1677. PubMed ID: 33342981
[No Abstract] [Full Text] [Related]
26. Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trial.
Hamaguchi T; Shimada Y; Mizusawa J; Kinugasa Y; Kanemitsu Y; Ohue M; Fujii S; Takiguchi N; Yatsuoka T; Takii Y; Ojima H; Masuko H; Kubo Y; Mishima H; Yamaguchi T; Bando H; Sato T; Kato T; Nakamura K; Fukuda H; Moriya Y
Lancet Gastroenterol Hepatol; 2018 Jan; 3(1):47-56. PubMed ID: 29079411
[TBL] [Abstract][Full Text] [Related]
27. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.
Joensuu H; Kellokumpu-Lehtinen PL; Huovinen R; Jukkola-Vuorinen A; Tanner M; Kokko R; Ahlgren J; Auvinen P; Paija O; Helle L; Villman K; Nyandoto P; Nilsson G; Pajunen M; Asola R; Poikonen P; Leinonen M; Kataja V; Bono P; Lindman H
J Clin Oncol; 2012 Jan; 30(1):11-8. PubMed ID: 22105826
[TBL] [Abstract][Full Text] [Related]
28. Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations.
Clifton K; Gutierrez-Barrera A; Ma J; Bassett R; Litton J; Kuerer H; Moulder S; Albarracin C; Hortobagyi G; Arun B
Breast Cancer Res Treat; 2018 Jul; 170(1):101-109. PubMed ID: 29470805
[TBL] [Abstract][Full Text] [Related]
29. Weekly paclitaxel, capecitabine, and bevacizumab with maintenance capecitabine and bevacizumab as first-line therapy for triple-negative, metastatic, or locally advanced breast cancer: Results from the GINECO A-TaXel phase 2 study.
Ferrero JM; Hardy-Bessard AC; Capitain O; Lortholary A; Salles B; Follana P; Herve R; Deblock M; Dauba J; Atlassi M; Largillier R
Cancer; 2016 Oct; 122(20):3119-3126. PubMed ID: 27412268
[TBL] [Abstract][Full Text] [Related]
30. Impressive Response to Capecitabine in a Patient with Obstructive Jaundice due to Metastatic Triple-Negative Breast Cancer.
Sattwika PD; Oktariani S; Leo B; Sagiran ; Iqbal M; Choridah L; Bayupurnama P; Kurnianda J; Hutajulu SH
Oncol Res Treat; 2019; 42(11):607-611. PubMed ID: 31557756
[TBL] [Abstract][Full Text] [Related]
31. Irinotecan and capecitabine combination chemotherapy in a patient with triple-negative breast cancer relapsed after adjuvant chemotherapy with anthracycline and taxane.
Lee A; Go SI; Lee WS; Lee US; Kim MJ; Kang MH; Lee GW; Kim HG; Kang JH; Jeon KN; Cho JM; Lee JH
Tumori; 2015 Mar; 101(1):e9-e12. PubMed ID: 25702650
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast cancer.
Fedele P; Marino A; Orlando L; Schiavone P; Nacci A; Sponziello F; Rizzo P; Calvani N; Mazzoni E; Cinefra M; Cinieri S
Eur J Cancer; 2012 Jan; 48(1):24-9. PubMed ID: 21775129
[TBL] [Abstract][Full Text] [Related]
33. A Pilot Study of Extended Adjuvant Therapy with Metronomic Docetaxel for Patients with Operable Triple-Negative Breast Cancer.
Abdelmaksoud BA; Mohammed A; Toam MM
Asian Pac J Cancer Prev; 2020 Mar; 21(3):749-754. PubMed ID: 32212803
[TBL] [Abstract][Full Text] [Related]
34. Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers.
Marangoni E; Laurent C; Coussy F; El-Botty R; Château-Joubert S; Servely JL; de Plater L; Assayag F; Dahmani A; Montaudon E; Nemati F; Fleury J; Vacher S; Gentien D; Rapinat A; Foidart P; Sounni NE; Noel A; Vincent-Salomon A; Lae M; Decaudin D; Roman-Roman S; Bièche I; Piccart M; Reyal F
Clin Cancer Res; 2018 Jun; 24(11):2605-2615. PubMed ID: 29463559
[No Abstract] [Full Text] [Related]
35. Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine.
O'Shaughnessy J; Koeppen H; Xiao Y; Lackner MR; Paul D; Stokoe C; Pippen J; Krekow L; Holmes FA; Vukelja S; Lindquist D; Sedlacek S; Rivera R; Brooks R; McIntyre K; Brownstein C; Hoersch S; Blum JL; Jones S
Clin Cancer Res; 2015 Oct; 21(19):4305-11. PubMed ID: 26041745
[TBL] [Abstract][Full Text] [Related]
36. Capecitabine combined with docetaxel versus vinorelbine followed by capecitabine maintenance medication for first-line treatment of patients with advanced breast cancer: Phase 3 randomized trial.
Wang J; Xu B; Yuan P; Ma F; Li Q; Zhang P; Cai R; Fan Y; Luo Y; Li Q
Cancer; 2015 Oct; 121(19):3412-21. PubMed ID: 26096296
[TBL] [Abstract][Full Text] [Related]
37. Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine.
Pivot X; Im SA; Guo M; Marmé F
Breast Cancer; 2018 May; 25(3):370-374. PubMed ID: 29302858
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of oral administration of cystine and theanine in patients with colorectal cancer undergoing capecitabine-based adjuvant chemotherapy after surgery: study protocol for a multi-institutional, randomised, double-blinded, placebo-controlled, phase II trial.
Hamaguchi R; Tsuchiya T; Miyata G; Sato T; Takahashi K; Ariyoshi K; Oyamada S; Iwase S
BMJ Open; 2018 Jul; 8(7):e021442. PubMed ID: 30030317
[TBL] [Abstract][Full Text] [Related]
39. Systemic treatment with capecitabine as maintenance therapy in patients with recurring or metastatic breast cancer: experience in the Oncology Hospital, National Medical Center Siglo XXI, Mexican Social Security Institute.
Segura-González M; Quintana-Quintana M
Med Oncol; 2015 Apr; 32(4):93. PubMed ID: 25720523
[TBL] [Abstract][Full Text] [Related]
40. Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials.
Dieci MV; Mathieu MC; Guarneri V; Conte P; Delaloge S; Andre F; Goubar A
Ann Oncol; 2015 Aug; 26(8):1698-704. PubMed ID: 25995301
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
